RxDoctor Payments Data

R Swamy Venuturupalli, MD

Rheumatology · Beverly Hills, CANPI 1063437648

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,551 of the $13,745 with a category attached, or 62.2%. 27 manufacturers reported payments, led by Pfizer at 42.2% of the total. Reporting peaked in 2022 at $6,436 and has fallen 67.8% since, to $2,072 in 2025.

$13,745in general payments, 2019–2025

Across 375 payments — averaging $36.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • AbbVie$2K
  • Amgen$2K
  • Novartis$2K
  • Johnson & Johnson$455
  • Radius Health, Inc.$226
  • plus $1K from 21 others
$925,812in research payments, 2019–2025

Across 167 payments — averaging $5543.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Navidea Biopharmaceuticals, Inc.$208K
  • Pfizer$161K
  • Argenx US, Inc.$138K
  • Novartis$107K
  • Mallinckrodt Hospital Products Inc.$85K
  • E.r. Squibb & Sons, L.L.C.$83K
  • plus $143K from 4 others

What the payments were for

  • Speaking & faculty fees$5,00036%
  • Food & beverage$8,55162%
  • Education$1941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,745 in reported general payments places this provider in the 75th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$6,728,243
Medicare patients
881
Services billed
349,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4624$69,572
Gamunex-CImmune Globul G/Gly/Iga Avg 4620$32,817
Mycophenolate Mofetil11$1,650
Hydroxychloroquine Sulfate23$905
MethotrexateMethotrexate Sodium25$376
Leucovorin Calcium12$373
Prednisone50$364
Duloxetine Hcl17$346
Ibandronate Sodium13$288
Tramadol Hcl21$207
Methylprednisolone15$119

Paid to pharmacies, not to this prescriber.

Other rheumatology in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →